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Introduction
 Angiogenesis is the formation of new blood vessels from preex-
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isting blood vessels, whereas arteriogenesis is the enlarging of ex-
isting blood vessels to form collaterals.1) The exact molecular mech-
anisms that drive neovascularization remain still unclear. Vascular en-
dothelial growth factor-A (or simply VEGF) is a growth factor in-
volved in angiogenesis and arteriogenesis.2)3) VEGF binds to Vascular 
endothelial growth factor receptor (VEGFR-1/Flt-1) and VEGFR-2 
(KDR/Flk-1), but with an approximate 10-fold higher affinity for VE-
GFR-1.2)3) Whereas VEGFR-2 mediates almost all of the known cel-
lular responses to VEGF, VEGFR-1 is thought to modulate VEGFR-2 
signaling.4) Angiopoietin (Ang)-1 and Ang-2 function as regulators 
of angiogenesis and arteriogenesis.5-8) Both Angs bind to the extra-
cellular domain of the Tie-2 receptor of endothelial cells.5)6) Where-
as Ang-2 destabilizes the vessel to make it sensitive to angiogenic 
growth factors such as VEGF, Ang-1 promotes vascular stabilization 
and counteracts VEGF-induced angiogenesis.5)6) Soluble forms of 
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both VEGFR-1 and Tie-2 are produced and secreted into the circula-
tion, where they can bind their respective growth factors and in-
hibit angiogenesis.9-11) Whereas soluble VEGFR-1 (sFlt-1) is pro-
duced by alternative splicing of the VEGFR-1 gene, soluble Tie-2 is 
the result of proteolytic cleavage from the full-length membrane-
bound receptor.9)10) The presence of collateral circulation in patients 
with acute myocardial infarction (AMI) undergoing primary percu-
taneous coronary intervention (PCI) has been reported to be asso-
ciated with smaller infarct size and more preserved left ventricular 
function.12) Sudden ischemia elicited by myocardial infarction in-
duces a compensatory response to improve myocardial perfusion 
by angiogenesis and arteriogenesis.13) However, well developed 
collateral arteries are observed only in a minority of patients at the 
time of primary PCI.14) Reasons for considerable interindividual vari-
ability in the extent of collateral formation remain uncertain. The 
purpose of the present study was to investigate the relationship be-
tween degree of collateral circulation and plasma levels of factors 
that regulate angiogenesis and arteriogenesis. 
Subjects and Methods
Study subjects
A total of 59 consecutive patients (mean age, 59±10 years) with 
ST-segment elevation myocardial infarct (STEMI) from the registry 
of the Infarction Prognosis Study, a prospective AMI cohort study 
at the Severance Cardiovascular Hospital, who underwent success-
ful primary PCI within 12 hours of pain onset during the period be-
tween July, 2007 and October 2008 were enrolled in this study. The 
Infarction Prognosis Study was approved by the hospital institution-
al review board and performed according to good clinical practice 
standards. Written informed consent was obtained from each pa-
tient before enrollment. The diagnosis of STEMI was based on 
acute typical chest pain with electrocardiogram findings (ST-seg-
ment elevation of ≥0.2 mV in precordial leads and ≥0.1 mV in limb 
leads), and elevated cardiac troponin T >0.01 ng/mL. All subjects 
showed a total or subtotal occlusion of the infarct-related artery 
with Thrombolysis in Myocardial Infarction (TIMI) flow of 0 or 1 on 
coronary angiography prior to primary PCI. We excluded patients 
with the following: a past history of old myocardial infarction, hav-
ing undergone a previous coronary artery bypass surgery, chronic 
total occlusion, renal failure (serum creatinine >2.0 mg/dL) and pre-
sence of significant stenosis in non-infarct related arteries requir-
ing additional revascularization. 
Grading of coronary collaterals and primary percutaneous 
coronary intervention
All patients received loading doses of 250 mg aspirin, 600 mg 
clopidogrel, and 70 IU/kg of intravenous heparin before primary PCI. 
Right and left coronary angiography was performed via femoral 
artery using standard Judkins technique. Degrees of coronary artery 
stenosis and collateral circulation were estimated visually by 2 in-
dependent cardiologists who were blinded to the clinical informa-
tion of patients. Coronary collateral flow was graded according to 
the Rentrop scoring system15) as follows: 0, no filling of any collat-
eral vessels; 1, filling of side branches of the artery to be perfused 
by collateral vessels without visualization of the epicardial segment; 
2, partial filling of the epicardial artery by collateral vessels; and 3, 
complete filling of the epicardial artery by collateral vessels. If col-
lateral circulation to the infarct territory was developed from more 
than 1 location, the site with the highest grade was taken into ac-
count.
 All PCIs were performed using a standard technique. A successful 
PCI was defined as a final TIMI grade 3 flow of the infarct-related 
artery with <30% residual stenosis. Abciximab was administered 
during the procedure at the operator’s discretion. After PCI, aspirin 
(100 mg/day) was continued indefinitely, and clopidogrel (75 mg/
day) was administered for at least 6 months.
Blood sample collection and laboratory analysis
Blood samples were obtained from an antecubital vein without 
stasis in all patients immediately after admission in the emergency 
department and before the administration of heparin. Further blood 
samples were taken at 24 hours and 48 hours after primary PCI in 
the same manner from the antecubital vein in all patients. The blo-
od samples, anticoagulated with ethylenediaminetetraacetic acid 
(EDTA), were immediately centrifuged at 3000 rpm for 10 minutes at 
4°C, and an aliquot of the EDTA-plasma was stored at -80°C until 
analyzed. Plasma levels of VEGF-A165, sFlt-1, Ang-2, sTie-2 were 
measured by commercially available enzyme-linked immunosor-
bent assay kits (R&D Systems, Minneapolis, MN, USA) according to 
the manufacturer’s instruction.
Statistical analysis
Statistical analysis was performed using Statistical Package for the 
Social Sciences (SPSS) 18.0 for Windows (SPSS Inc., Chicago, IL, 
USA). Categorical variables were expressed as percentages and 
compared using chi-square tests between the 2 patient groups. 
When the expected cell number was <5, Fisher’s exact tests were 
used. Continuous data were expressed as mean±SD. Continuous 
variables were analyzed using unpaired t-tests and the Mann-Whit-
ney U-test, as appropriate. Correlations between creatine kinase-
MB (CK-MB) and growth factor levels were tested using Spearman’s 
rank correlation. The Paired t-test was performed to compare the 
plasma levels of each angiogenic factor between different time po-
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ints. For all tests, two-tailed p<0.05 were considered significant.
Results
Clinical and angiographic characteristics
Coronary angiography prior to PCI showed collateral circulation 
of Rentrop grade 0 in 14, grade 1 in 20, grade 2 in 15, and grade 3 
in 10 patients. Patients were divided according to the Rentrop col-
lateral circulation grade into group I (grade 0 or 1, n=34) or group II 
(grade 2 or 3, n=25). Clinical and angiographic characteristics are 
summarized in Table 1. Risk factors such as age, gender, hyperten-
sion, hypercholesterolemia, and smoking did not differ between the 
two patient groups. However, diabetes mellitus (41.2% vs.16.0%, 
p=0.038) were more frequently observed in group I, whereas pre-
vious history of angina (18.2% vs. 50%, p=0.011) and multi-vessel 
disease (47.1% vs. 72.0%, p=0.047) were more frequent in group II. 
Previous use of statin, door-to-balloon time, location of infarct-
related artery, and serum levels of biomarkers such as cardiac tro-
ponin-T, CK-MB, and high sensitivity C-reactive protein did not dif-
fer between the two groups. However, group II showed significant 
lower left ventricular ejection fraction (47.2±9.8% vs. 41.9±9.6%, 
p=0.049) and a trend toward longer pain-to-balloon time (4.3±2.9 
vs. 6.1±6.9, p=0.173) compared to group I. 
Vascular endothelial growth factor, soluble VEGF receptor, 
angiopoietin-2, and sTie2
There were increasing plasma levels of VEGF from admission to 
the emergency room at 24 and 48 hours after PCI. However, there 
was no statistically significant difference in VEGF plasma levels be-
tween the 2 patient groups at any time point (Table 2) (Fig. 1A). Plas-
ma levels of sFlt-1, a VEGF antagonist, were initially elevated, how-
ever decreased gradually after PCI (Table 2) (Fig. 1B). Similarly to VEGF, 
sFlt-1 plasma levels did not differ between the 2 patient groups. In 
contrast to VEGF, Ang-2 plasma levels were highest on admission 
and thereafter decreased at 24 and 48 hours after PCI (Table 2) (Fig. 
1C). Ang-2 plasma level was significantly higher in group I at 48 
hours after PCI than group II (1043.0±785.4 vs. 621.5±381.2 pg/mL, 
p=0.035). Ang-2 plasma levels on admission (1581.3±594.1 vs. 
1364.7±624.5 pg/mL, p=0.181) and 24 hours after PCI (805.8±482.7 
vs. 634.6±404.5 pg/mL, p=0.227) tend to be higher in group I than 
in group II. The difference in plasma levels of VEGF, sFlt-1, and Ang-2 
were statistically significant between baseline and 24 hours and 
between baseline and 48 hours in both groups (Table 2). However, 
the plasma levels did not change significantly from 24 hours to 48 
hours. sTie-2 did not show significant interval changes in plasma 
concentrations from admission to 24 hours or 48 hours after PCI 
in group I, but sTie-2 level decreased significantly from baseline to 
24 hours or 48 hours in group II (Table 2) (Fig. 1D). However, there 
was also no statistically significant difference in sTie-2 plasma lev-
els at any time point between the 2 patient groups. 
There were no significant correlations between initial CK-MB and 
initial VEGF levels (r=0.109, p=0.409) and between initial CK-MB and 
initial Ang-2 levels (r=0.005, p=0.969). Peak CK-MB level did not 
correlate with any of VEGF (r=0.04, p=0.795) or Ang-2 (r=0.149, p= 
0.341) levels at 48 hours. 
Discussion
Major findings of the present study were the following: 1) Ang-
2 plasma levels in patients with STEMI were elevated on admission 
and fell gradually after primary PCI. 2) Ang-2 plasma levels tend to 
be slightly higher at baseline and significantly higher at 48 hours af-
ter PCI in patients with poor collateral circulation (grade 0/1) than in 
patients with collateral grade 2/3. 3) VEGF plasma levels were rela-
Table 1. Baseline characteristics
Group I Group II p
n 34 25
Age (years) 59.9±9.9 57.2±10.3 0.321
Male (%) 22 (64.7) 21 (84.0) 0.100
Hypertension (%) 19 (55.9) 9 (36.0) 0.131
DM (%) 14 (41.2) 4 (16.0) 0.038
Hypercholesterolemia (%) 19 (55.9) 13 (52.0) 0.767
Smoking (%) 15 (44.1) 7 (28) 0.206
Previous angina (%) 6 (18.2) 12 (50) 0.011
Previous use of statin (%) 6 (17.6) 5 (20.0) 0.819
Pain-to-balloon time
  (hour)
4.3±2.9 6.1±6.9 0.173
Door-to-balloon time
  (minute)
68.0±11.5 69.8±10.1 0.541
Infarct-related artery (%) 0.242
    LAD 18 (52.9) 9 (36.0)
    LCX 1 (2.9) 3 (12.0)
    RCA 15 (44.1) 13 (52.0)
Multi-vessel disease (%) 16 (47.1) 18 (72.0) 0.047
Killip class (III or IV) (%) 2 (6.1) 4 (16.7) 0.243
LVEF (%) 47.2±9.8 41.9±9.6 0.049
CK-MB initial 17.5±35.3 22.5±34.9 0.591
CK-MB peak 287.0±182.9 285.5±178.4 0.976
cTn-T 0.25±0.50 0.28±0.55 0.752
hsCRP 6.87±11.01 3.48±7.61 0.216
LAD: left anterior descending, LCX: left circumflex, RCA: right coronary artery, 
LVEF: left ventricular ejection fraction, cTn-T: cardiac troponin-T, hsCRP: 
high sensitivity C-reactive protein, CK-MB: creatine kinase-MB, DM: diabe-
tes mellitus
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tively low initially, however, and increased gradually after PCI. 4) 
sFlt-1, an antagonist of VEGF, showed changes in plasma levels, 
which were the reverse to those of VEGF. sFlt-1 plasma levels were 
highest on admission and decreased with time after PCI. 5) VEGF 
and sFlt-1 levels did not differ within 48 hours according to the ex-
tent of collateral circulation. 6) sTie-2 was decreased after PCI only 
in the patient group with well developed collaterals. However, sTie-
2 did not differ significantly between the patient groups during the 
time course. 
Coronary collaterals offer an important alternative source of blo-
od supply when the original vessels occlude due to AMI. In human 
hearts, an extensive pre-existing collateral network is known to be 
present.16) The pre-existent collateral vessels usually enlarge upon 
closure of an epicardial coronary artery, resulting in large collateral 
conduit arteries. Generally, collateral arteries are evident only in a 
minority (10-40%) of AMI patients undergoing PCI.14) According to 
an animal study, de novo collateral artery formation after acute cor-
onary occlusion is usually angiographically notable at least 24 hours 
after the onset of chest paint.17) Previous studies demonstrated 
that presence of coronary collateral circulation to the infarct zone 
was associated with preserved myocardial perfusion and left ven-
tricular (LV) function, reduced in-hospital death, and increased 
survival of AMI patients.12)18) In our study, patients with collaterals of 
Rentrop grade 2 or 3 had more frequently previous angina and 
multi-vessel disease. Diabetes mellitus was associated with poor 
formation of collateral circulation. These findings were consistent 
with previous reports. Pre-infarction angina, severity of the infarct-
related artery stenosis, right coronary artery occlusion, multi-vessel 
disease and cholesterol lowering therapy had been suggested as 
predictors of collateral circulation in patients presenting with AMI.14) 
Table 2. Plasma levels of VEGF, sFlt-1, Ang-2, and sTie-2 at different time points
Group I Group II p
VEGF (pg/mL)
ER 36.7±54.9 39.2±74.9 0.884
24 hours post PCI 326.0±268.5 424.4±298.5 0.274
48 hours post PCI 471.3±263.8 488.0±490.1 0.887
Δ (from ER to 24 hours) 285.2±262.8* 382.0±293.6* 0.273
Δ (from ER to 48 hours) 433.4±280.6* 445.6±474.5* 0.917
Δ (from 24 hours to 48 hours) 55.1±125.5 35.4±81.5 0.555
sFlt-1 (pg/mL)
ER 797.5±369.9 785.6±309.1 0.897
24 hours post PCI 107.4±138.6 76.5±85.5 0.398
48 hours post PCI 52.9±42.3 41.1±25.8 0.281
Δ (from ER to 24 hours) -588.6±298.8* -645.2±304.2* 0.552
Δ (from ER to 48 hours) -672.3±373.5* -680.5±297.6* 0.937
Δ (from 24 hours to 48 hours) -55.1±125.5 -35.4±81.5 0.555
Angiopoietin-2 (pg/mL)
ER 1581.3±594.1 1364.7±624.5 0.181
24 hours post PCI 805.8±482.7 634.6±404.5 0.227
48 hours post PCI 1043.0±785.4 621.5±381.2 0.035
Δ (from ER to 24 hours) -728.2±620.2* -614.0±368.1* 0.481
Δ (from ER to 48 hours) -447.5±865.7* -627.1±543.6* 0.426
Δ (from 24 hours to 48 hours) 153.9±433.9 -13.1±296.8 0.161
sTie-2 (ng/mL)
ER 3.0±0.8 3.2±0.5 0.273
24 hours post PCI 3.0±0.6 2.9±0.6 0.638
48 hours post PCI 2.9±0.8 2.8±0.7 0.517
Δ (from ER to 24 hours) 0.1±0.5 -0.3±0.5* 0.013
Δ (from ER to 48 hours) -0.1±0.9 -0.4±0.7* 0.054
Δ (from 24 hours to 48 hours) -0.1±0.7 -0.2±0.5 0.809
*Statistically significant difference between the two measurement time points (p<0.05). VEGF: vascular endothelial growth factor, ER: emergency room, 
PCI: percutaneous coronary intervention, sFlt-1: soluble VEGF receptor
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However, against our expectation, the patient group with collateral 
grade 0/1 had higher LV ejection fractions and showed a trend to-
ward lower Killip class compared to the patient group with collateral 
grade 2/3. This observation may be explained by the higher fre-
quency of multivessel disease and the tendency toward a longer 
pain-to-balloon time in the patient group with collateral grade 2/3 
compared to the patient group with poor collaterals. Multivessel dis-
ease usually involves a larger myocardial territory exposed to isch-
emia. Delayed reperfusion may have resulted in more decreased LV 
systolic function, however potentially provided more time to re-
cruit collateral vessels. 
Angiogenesis, as well as arteriogenesis, is a highly complex pro-
cess that requires coordinated interaction and cooperation between 
endothelial cells, extracellular matrix and peri-endothelial cells un-
der the control of growth factors and their receptors. VEGF and 
Ang-2 are important growth factors involved both in angiogenesis 
and arteriogenesis.2)3)5-8) sFlt-1 and sTie-2 are circulating decoyed re-
ceptors of VEGF and Angio-2, respectively that counteract the ac-
tions of the corresponding growth factors. There have been only a 
little data on the plasma levels of these factors in AMI patients. 
Ogawa et al.19) reported that serum VEGF level was higher in AMI 
patients than in patients with stable angina and control healthy 
subjects. Similarly, Iribarren et al.20) reported that VEGF-A and Ang-2 
levels were significantly higher in AMI cases than in controls. Hojo 
et al.21) performed serial measurements of serum VEGF levels and 
found that the VEGF levels elevated gradually after the onset of 
AMI. The peak VEGF level was reached on day 14. Lee et al.22) also 
investigated serial changes of plasma Ang-1, Ang-2, sTie-2, and 
VEGF levels from baseline to 18 weeks in AMI. In their study, Ang-1 
levels were unchanged from baseline to 6 weeks, but were elevated 
at 18 weeks. Ang-2 changes followed a biphasic pattern, being hi-
gher at baseline and 6 weeks, but lower at 48 hours and 18 weeks. 
sTie-2 levels increased from baseline and remained elevated in the 
chronic phase. VEGF peaked at 6 weeks and then decreased toward 
baseline at 18 weeks. The observation of delayed increase in VEGF 
levels was supported by the report by Lee et al.23) that VEGF mes-
senger ribonucleic acid (mRNA) expression was only found in human 
myocardial specimens of “late” infarct (onset of 24 to 120 hours 
before surgery), whereas Hypoxia-inducible factor (HIF)-1 mRNA 
was detected in specimens of “acute” infarct (<24 hours before sur-
gery). They suggested that HIF-1 may contribute to the limitation of 
infarct size by increasing levels of VEGF and thereby promoting an-
giogenesis. Ang-2 levels are reported to be upregulated by hypoxia.5) 
Furthermore, previous studies have revealed an ambivalent role of 
Fig. 1. Plasma levels of VEGF (A), sFlt-1 (B), Ang-2 (C), and sTie-2 (D) at baseline in emergency room and at 24 and 48 hours after primary percutaneous 
coronary intervention. Group I (n=34): rentrop collateral circulation grade 0 or 1; group II (n=25): grade 2 or 3. VEGF: vascular endothelial growth factor, 
sFlt: soluble VEGF receptor, Ang-2: angiopoietin-2, ER: emergency room, PCI: percutaneous coronary intervention.
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Ang-2 in angiogenesis, depending on the availability of VEGF. For 
instance, Ang-2 and VEGF act synergistically to produce a stable 
and functional microvasculature.5)24)25) In the absence of VEGF, how-
ever, Ang-2 competitively antagonizes Ang-1-induced Tie-2 phos-
phorylation and thereby induces vessel regression. The clinical im-
plication of the elevated plasma levels of Ang-2 without rise of VEGF 
levels at baseline in our study is uncertain. The Ang-2 plasma level 
tended to be lower prior to primary PCI and was significantly lower 
at 48 hours after PCI in patients with collaterals of grade 2/3 com-
pared to those with poor collaterals. We assume that the presence 
of well developed collaterals might not have required higher levels 
of Ang-2 in response to acute ischemia. However, LV ejection was 
actually higher in the patient group with collateral grade 0/1 in our 
study. There was no significant correlation between Ang-2 and CK-
MB levels. Furthermore, we cannot explain within the limits of this 
study why the VEGF levels did not differ between the patient groups. 
The clinical implications of our findings remain inconclusive. How-
ever, to our knowledge, our study is the first clinical study demon-
strating the temporal relationships among VEGF, Ang-2, sFlt-1, and 
sTie-2 in STEMI patients treated with primary PCI. Therefore, our 
study may deliver the bases for further clinical studies.
Several study limitations need to be acknowledged. First, the sam-
ple size was small, which limits statistical power. Therefore, more de-
tailed analysis on various clinical factors or drugs that may have in-
fluence the plasma levels of the growth factors could not be per-
formed. Second, the serial measurement of various growth factors 
was limited to the first 48 hours. Therefore, we cannot rule out the 
possibility that the plasma levels of growth factors differ between 
the patient groups later than 48 hours after AMI onset. 
In conclusion, our study demonstrated that the plasma levels of 
Ang-2 and VEGF have different temporal profiles after the onset of 
AMI. There was a subtle difference in Ang-2 plasma levels accord-
ing to the extent of collateral circulation development. The presence 
of collateral circulation in STEMI patients undergoing primary PCI 
was associated with a lesser rise in plasma levels of Ang-2. VEGF 
showed a delayed response to acute ischemia compared to Ang-2. 
The detailed interactions and role of various angiogenic factors in the 
setting of AMI needs to be investigated in further studies. 
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